Literature DB >> 10557105

ATM: a mediator of multiple responses to genotoxic stress.

G Rotman1, Y Shiloh.   

Abstract

The ATM protein kinase is the product of the gene responsible for the pleiotropic recessive disorder ataxia-telangiectasia. ATM-deficient cells show enhanced sensitivity and greatly reduced responses to genotoxic agents that generate DNA double strand breaks (DSBs), such as ionizing radiation and radiomimetic chemicals, but exhibit normal responses to DNA adducts and base modifications induced by other agents. Therefore, DSBs are most likely the predominant signal for the activation of ATM-mediated pathways. Identification of the ATM gene triggered extensive research aimed at elucidating the numerous functions of its large multifaceted protein product. While ATM has both nuclear and cytoplasmic functions, this review will focus on its roles in the nucleus where it plays a central role in the very early stages of damage detection and serves as a master controller of cellular responses to DSBs. By activating key regulators of multiple signal transduction pathways, ATM mediates the efficient induction of a signaling network responsible for repair of the damage, and for cellular recovery and survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557105     DOI: 10.1038/sj.onc.1203124

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

Review 1.  The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone.

Authors:  R A Gatti; S Becker-Catania; H H Chun; X Sun; M Mitui; C H Lai; N Khanlou; M Babaei; R Cheng; C Clark; Y Huo; N C Udar; R K Iyer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

2.  Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium.

Authors:  P E Bonnen; M D Story; C L Ashorn; T A Buchholz; M M Weil; D L Nelson
Journal:  Am J Hum Genet       Date:  2000-11-14       Impact factor: 11.025

Review 3.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

4.  Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation.

Authors:  B Xu; M B Kastan
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

6.  ATM-dependent phosphorylation of the checkpoint clamp regulates repair pathways and maintains genomic stability.

Authors:  Min Hwa Shin; Ming Yuan; Hao Zhang; Joseph B Margolick; Mihoko Kai
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

7.  Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.

Authors:  Yun-Ling Zheng; Christopher A Loffredo; Anthony J Alberg; Zhipeng Yu; Raymond T Jones; Donna Perlmutter; Lindsey Enewold; Mark J Krasna; Rex Yung; Peter G Shields; Curtis C Harris
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Mammalian meiosis involves DNA double-strand breaks with 3' overhangs.

Authors:  Drora Zenvirth; Carmelit Richler; Amit Bardhan; Frédéric Baudat; Ari Barzilai; Jacob Wahrman; Giora Simchen
Journal:  Chromosoma       Date:  2003-01-25       Impact factor: 4.316

9.  PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus.

Authors:  Jee-Yin Ahn; Rong Rong; Xuesong Liu; Keqiang Ye
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

10.  The combined status of ATM and p53 link tumor development with therapeutic response.

Authors:  Hai Jiang; H Christian Reinhardt; Jirina Bartkova; Johanna Tommiska; Carl Blomqvist; Heli Nevanlinna; Jiri Bartek; Michael B Yaffe; Michael T Hemann
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.